O
Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
LSE:OBI
Price:
10.75
GBX
Market Closed
Market Cap:
£55.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
CA |
|
Pearson PLC
LSE:PSON
|
UK |
|
Lintes Technology Co Ltd
TWSE:6715
|
TW |
|
Samsara Inc
NYSE:IOT
|
US |
|
C
|
Credit Bureau Asia Ltd
SGX:TCU
|
SG |
|
Keppel REIT
SGX:K71U
|
SG |
|
Saray Matbaacilik Kagitcilik Kirtasiyecilik Ticaret ve Sanayi AS
IST:SAMAT.E
|
TR |
|
Future Venture Capital Co Ltd
TSE:8462
|
JP |
|
C
|
Cannabist Company Holdings Inc
NEO:CBST
|
US |
|
Good Energy Group PLC
LSE:GOOD
|
UK |
|
S
|
Shizuki Electric Co Inc
TSE:6994
|
JP |
|
Etablissements Maurel et Prom SA
PAR:MAU
|
FR |
|
Dexxos Participacoes SA
BOVESPA:DEXP3
|
BR |
|
C
|
CNSIG Inner Mongolia Chemical Industry Co Ltd
SSE:600328
|
CN |
|
Sanko Pazarlama Ithalat Ihracat AS
IST:SANKO.E
|
TR |
|
United Utilities Group PLC
LSE:UU
|
UK |
|
Loop Media Inc
OTC:LPTV
|
US |
|
Glunz & Jensen Holding A/S
CSE:GJ
|
DK |
|
Pony Testing International Group Co Ltd
SZSE:300887
|
CN |
|
D
|
Deutsche Konsum REIT-AG
LSE:0RDE
|
DE |
|
W
|
Wheeler Real Estate Investment Trust Inc
NASDAQ:WHLR
|
US |
Income Statement
Earnings Waterfall
Ondine Biomedical Inc
Ondine Biomedical Inc
Income Statement
Ondine Biomedical Inc
Ondine Biomedical Inc
Currency: CAD
| Mar-2011 | Jun-2011 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
1
+65%
|
3
+310%
|
1
-67%
|
1
-25%
|
1
+26%
|
1
+50%
|
2
+36%
|
2
+25%
|
2
+8%
|
|
| Gross Profit | |||||||||||
| Cost of Revenue |
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Gross Profit |
0
N/A
|
0
+43%
|
1
+572%
|
0
-69%
|
0
-27%
|
0
+37%
|
1
+78%
|
1
+40%
|
1
+35%
|
1
+10%
|
|
| Operating Income | |||||||||||
| Operating Expenses |
(4)
|
(4)
|
(19)
|
(53)
|
(19)
|
(20)
|
(16)
|
(16)
|
(21)
|
(26)
|
|
| Selling, General & Administrative |
(2)
|
(2)
|
(13)
|
(16)
|
(12)
|
(12)
|
(10)
|
(9)
|
(11)
|
(11)
|
|
| Research & Development |
(3)
|
(3)
|
(5)
|
(5)
|
(6)
|
(6)
|
(5)
|
(6)
|
(9)
|
(14)
|
|
| Depreciation & Amortization |
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
1
|
1
|
0
|
(32)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(4)
N/A
|
(4)
-6%
|
(18)
-322%
|
(53)
-202%
|
(19)
+65%
|
(20)
-5%
|
(15)
+25%
|
(15)
+1%
|
(19)
-33%
|
(24)
-24%
|
|
| Pre-Tax Income | |||||||||||
| Interest Income Expense |
0
|
0
|
(1)
|
(1)
|
1
|
1
|
0
|
(0)
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
(32)
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
1
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(3)
N/A
|
(3)
-9%
|
(50)
-1 456%
|
(54)
-8%
|
(19)
+64%
|
(19)
+3%
|
(14)
+23%
|
(14)
+1%
|
(19)
-34%
|
(24)
-25%
|
|
| Net Income | |||||||||||
| Tax Provision |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(3)
|
(3)
|
(50)
|
(54)
|
(19)
|
(19)
|
(14)
|
(14)
|
(19)
|
(24)
|
|
| Net Income (Common) |
(3)
N/A
|
(3)
-9%
|
(50)
-1 455%
|
(54)
-8%
|
(19)
+64%
|
(19)
+3%
|
(14)
+23%
|
(14)
+1%
|
(19)
-34%
|
(24)
-25%
|
|
| EPS (Diluted) |
-0.3
N/A
|
-0.35
-17%
|
-0.63
-80%
|
-0.27
+57%
|
-0.1
+63%
|
-0.1
N/A
|
-0.07
+30%
|
-0.06
+14%
|
-0.07
-17%
|
-0.07
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
